NMNH: 1. “Bonzyme” Whole-enzymatic method, environmental-friendly, no harmful solvent residues manufacturing powder. 2. Bontac is a very first manufacture in the world to produce the NMNH powder on the level of high purity, stability. 3. Exclusive “Bonpure” seven-step purification technology, high purity(up to 99%) and stability of production of NMNH powder 4. Self-owned factories and obtained a number of international certifications to ensure high quality and stable supply of products of NMNH powder 5. Provide one-stop product solution customization service
NADH: 1. Bonzyme whole-enzymatic method, environmental-friendly, no harmful solvent residues 2. Exclusive Bonpure seven-step purification technology, purity up higher than 98 % 3. Special patented process crystal form, higher stability 4. Obtained a number of international certifications to ensure high quality 5. 8 domestic and foreign NADH patents, leading the industry 6. Provide one-stop product solution customization service
NAD: 1. “Bonzyme” Whole-enzymatic method, environmental-friendly, no harmful solvent residues 2. Stable supplier of 1000+ enterprises around the world 3. Unique “Bonpure” seven-step purification technology, higher product content and higher conversion rate 4. Freeze drying technology to ensure stable product quality 5. Unique crystal technology, higher product solubility 6. Self-owned factories and obtained a number of international certifications to ensure high quality and stable supply of products
NMN: 1. “Bonzyme”Whole-enzymatic method, environmental-friendly, no harmful solvent residues 2. Exclusive“Bonpure”seven-step purification technology, high purity(up to 99.9%) and stability 3. Industrial leading technology: 15 domestic and international NMN patents 4. Self-owned factories and obtained a number of international certifications to ensure high quality and stable supply of products 5. Multiple in vivo studies show that Bontac NMN is safe and effective 6. Provide one-stop product solution customization service 7. NMN raw material supplier of famous David Sinclair team of Harvard University
Bontac Bio-Engineering (Shenzhen) Co., Ltd. (hereafter referred to as BONTAC) is a high-tech enterprise established in July 2012. BONTAC integrates R&D, production and sales, with enzyme catalysis technology as the core and coenzyme and natural products as main products. There are six major series of products in BONTAC, involving coenzymes, natural products, sugar substitutes, cosmetics, dietary supplements and medical intermediates.
As the leader of the global NMN industry, BONTAC has the first whole-enzyme catalysis technology in China. Our coenzyme products are widely used in health industry, medical & beauty, green agriculture, biomedicine and other fields. BONTAC adheres to independent innovation, with more than 170 invention patents. Different from the traditional chemical synthesis and fermentation industry, BONTAC has advantages of green low-carbon and high-value-added biosynthesis technology. What’s more, BONTAC has established the first coenzyme engineering technology research center at the provincial level in China which also is the sole in Guangdong Province.
In the future, BONTAC will focus on its advantages of green, low-carbon and high-value-added biosynthesis technology, and build ecological relationship with academia as well as upstream/downstream partners, continuously leading the synthetic biological industry and creating a better life for human beings.
It is a naturally occurring substance in humans and organisms. Judging from the fact that breast milk contains NMN, it can be said to be one of the nutrients that humans ingest at the beginning of life. Yellow and green vegetables also contain NMN, so it is different from medicine. NMN is a food of natural origin and is safe.
1. Introduction At present, vaccine is the preferred option for the prevention of foot-and-mouth disease (FMD), for which the adjuvant is essential due to its strong role in boosting immune response associated with vaccine antigens. Herein, Rh2 liposomes (Rh2-L) are prepared by ethano injection methods, then loaded into a double emulsion adjuvant and emulsified into a Water-in-Oil-in-Water (W/O/W) emulsion, together with FMDV antigen, for the prevention of FMD. 2. About FMD FMD, also known as aphthous fever, is a viral and fulminating infectious disease in which the foot-and-mouth disease virus (FMDV) violates hoofed livestock such as cattle, pigs and sheep. Since FMD is a zoonotic disease with high incidence and fast transmission speed, FMD vaccination is significant for those with long-term contact with livestock or low immunity such as the herders, veterinarians and children. 3.The significance of transform Rh2 into Rh2-L By transformation of Rh2 into Rh2-L, on the one hand, the poor solubility and hemolysis of Rh2 can be mitigated to a large extent. On the other hand, Rh2-L functions as a liposome. Noteworthily, liposome itself has been revealed to be an adjuvant in vaccine design to improve immune response by interacting with antigen-presenting cells (APCs), increasing the representation of immune stimulants to APCs, and stimulating innate immunity. 4. The immune-enhancing effect of Rh2-L on FMD vaccine Rh2-L has a immune-enhancing effect, as evidenced by an increase in humoral and cellular immune responses. In the FMDV model, the group of the FMD vaccine prepared with double emulsion adjuvants containing Rh2-L presents a more desirable protective effect relative to other groups. This group has a higher neutralizing antibody titer, stronger lymphocyte proliferation responses, and higher levels of cellular and humoral immune cytokine production, including IFN-γ and IL-4. 5. Conclusion Rh2-L can further boost the immune effect of the double emulsion adjuvant against foot-and-mouth disease, which may be a promising and powerful platform for subunit vaccine adjuvant. 6. Reference Saiya Miao, Qiufang Jing, Xuanyu Wang, et al. “Immuno-Enhancing Effect of Ginsenoside Rh2 Liposomes on Foot-and-Mouth Disease Vaccine”. Molecular Pharmaceutics. 2024 21 (1), 183-193. DOI: 10.1021/acs.molpharmaceut.3c00733 BONTAC advantages BONTAC is ·the first enterprise in China to provide mass production of ginsenosides (Rh2) by enzymatic synthesis. BONTAC has unique Bonzyme enzymatic synthesis technology. Our coenzyme products are widely used in health industry, medical & beauty, green agriculture, biomedicine and other fields. BONTAC has more than 160 invention patents, with strict third-party self-inspection. Both the high-quality product and excellent service can be better ensured here. BONTAC has 12 years of industry experience, which is worthy of your trust. Disclaimer This article is based on the reference in the academic journal. The relevant information is provide for sharing and learning purposes only, and does not represent any medical advice purposes. If there is any infringement, please contact the author for deletion. The views expressed in this article do not represent the position of BONTAC. Under no circumstances will BONTAC be held responsible or liable in any way for any claims, damages, losses, expenses, costs or liabilities whatsoever (including, without limitation, any direct or indirect damages for loss of profits, business interruption or loss of information) resulting or arising directly or indirectly from your reliance on the information and material on this website.
1. Introduction Ginseng has always been highly perceived as a valuable traditional Chinese medicine in China. Currently, much attention also has been paid to ginsenosides, the main active ingredients extracted from ginseng. Strikingly, ginsenoside Rh2, one of the most representative bioactive ginsenosides in Panax ginseng, has immunomodulatory, anti-inflammatory, and anti-tumor activities, showing a therapeutic role in numerous diseases. 2. The therapeutic effect of ginsenoside Rh2 * Enhance the immune function of the human body Ginsenoside Rh2 has the effect of enhancing the immune function of the patient's body. Notewothily, it can effectively reduce the toxicity left by chemotherapy in the human body by improving immunity. *Ameliorate neuropathic pain Intrathecal administration of ginsenoside Rh2 significantly attenuates SNI-induced mechanical allodynia and thermal hyperalgesia. The antinociceptive effect of Rh2 continued until 10 days after SNI surgeryn, showing a potential application value in pain therapy. Figure 1 Intrathecal injection of Rh2 inhibits neuropathic pain in mice * Suppress the inflammation Previous studies have revealed that ginsenoside Rh2 can inhibit spared nerve injury (SNI)-induced increase of proinflammatory cytokines (tumor necrosis factor-α, interleukin-1 and interleukin-6), and significantly inhibit lipopolysaccharide (LPS)-induced activation of BV2 cells. Figure 2 Intrathecal injection of Rh2 reduced expression of proinflammatory cytokines IL-1, IL-6 and TNF-α in SNI mice * Promote the synthesis of albumin Ginsenoside Rh2 acts as an immune regulator to promote the synthesis of albumin, which can provide heat for the human body, protect and stabilize the immunoglobulin in the blood. * Inhibit the growth of tumor cells Ginsenoside Rh2 exhibits a chemical structure similar to that of dexamethasone. In in vitro studies, it can suppress the growth and viability of various cancer cells, induce tumor cell cycle arrest and cellular apoptosis, trigger necrosis and autophagy in cancer cells, inhibit metastasis, and suppress angiogenesis. * Reversal of abnormal tumor differentiation Ginsenoside Rh2 has a differentiation-inducing effect on tumor cancer cells, and can effectively enhance the melanin production ability in cancer cells, thereby causing cancer cells to transform into normal cells in morphology. Table 1 Anticancer effects and mechanisms of ginsenoside‑Rh2 in in vivo studies 3. The difference between ginsenoside Rg3 and ginsenoside Rh2 Figure 3 Molecular struction of ginsenoside Rg3 and ginsenoside Rh2 Both ginsenoside Rg3 and ginsenoside Rh2 have been attested to achieve antitumor effects by strengthening the immune function of the body. Despite their similar mechanisms of action, differences still exist between ginsenoside Rg3 and ginsenoside Rh2. In terms of the molecular structure, ginsenoside Rh2 has only one glycosyl group, whereas ginsenoside Rg3 has two. In addition, ginsenoside Rh2 has a higher bioavailability than ginsenoside Rg3. Ginsenoside Rg3 is easy to be excreted from the body after being taken, and won't make much difference to the body. With regard to the intestinal absorption, ginsenotone Rh2 is about 5 times of ginsenotone Rg3. 4. Conclusion The monosaccharide ginsenoside Rh2 can effectively improve human immunity, enhance disease resistance, and reduce the risk of cancer. Relative to ginsenoside Rg3, ginsenoside Rh2 shows higher cost-efficiency in the intestinal absorption, application scope and efficacy, providing an upgraded health support. Product Features and advantages of BONTAC Ginsenoside Rh2 One-stop product solution customization service Multiple patents and strict third-party self-inspection The first national mass production of ginsenosides by enzymatic synthesis Unique Bonzyme enzymatic synthesis technology Reference [1] Fu, Yuan-Yuan et al. Ginsenoside Rh2 Ameliorates Neuropathic Pain by inhibition of the miRNA21-TLR8-mitogen-activated protein kinase axis. Molecular pain. 2022;18:17448069221126078. doi:10.1177/17448069221126078 [2] He XL, Xu XH, Shi JJ, et al. Anticancer Effects of Ginsenoside Rh2: A Systematic Review. Curr Mol Pharmacol. 2022;15(1):179-189. doi:10.2174/1874467214666210309115105 Disclaimer BONTAC shall hold no responsibility for any claims arising directly or indirectly from your reliance on the information and material on this website.
Introduction In light of a statistics report by World Health Organization (WHO), there are 18 million people suffering from rheumatoid arthritis (RA) worldwide in 2019, where the prevalence of female is 2.5 times that of male. This disorder greatly affects the life quality of patients and even causes disability in severe case. Noteworthily, mesenchymal stem cell-derived exosome (MSCs-exo) in combination with ginsenoside Rh2 has been unveiled to be effective in alleviating RA symptoms, holding a great promise as an adjuvant drug for RA. About RA RA represents a chronic autoimmune disease generally occurring in middle age, which is chiefly featured by vascular proliferation, synovium inflammation and the stiffness/swelling/deformation/pain of one or more joints. At present, the treatment of RA relies on corticosteroids, nonsteroidal anti-inflammatory drugs, synthetic disease-modifying anti-rheumatic drugs, and biological agents. Yet, long-term use of these drugs may be accompanied with various adverse effects such as infection, liver damage, gastrointestinal damage, and heart failure. MSCs vs. MSCs-exo MSCs, with multiple differentiation potential, can reduce joint inflammation in RA. Nevertheless, there are potential risks such as immunogenicity, heterogeneity of different batches of cells, tumorigenicity, and ethical issues, limiting the application of MSCs. MSCs-exo is small extracellular vesicle secreted by MSCs, whose diameter ranges from 30 to 150 nanometers. It can carry biologically active substances such as nucleic acids and small molecules, fulfilling the function of MSCs. Relative to MSCs, MSCs-exo has low immunogenicity and has no risk of tumor formation and ethical constraints. Research protocol A collagen-induced arthritis (CIA) model is constructed in rats, followed by the treatment of phosphate-buffered saline or single/combined therapy of MSCs-exo and ginsenoside Rh2. The rat fences are collected for 16 rRNA amplification sequencing and untargeted metabolomics analysis. Significant efficacy of MSCs-exo combined with ginsenoside Rh2 in RA The combined therapy of MSCs-exo and ginsenoside Rh2, to a large extent, ameliorates RA symptoms in CIA model rats, as manifested by the reduction of joint swelling as well as significant decline in arthritis score and paw thickness. Meanwhile, the histopathological changes in CIA model rats are apparently improved. Rh2 enhances the ability of MSC-exo to suppress the expression of inflammatory factors in synovium and cartilage of CIA model rats, as evidenced by the downregulation of TNF-α, IL-1β and IL-6 as well as upregulation of IL-10 in exo+Rh2 group. Besides, bone erosion in the ankle joints of CIA rats is improved, as attested by the obvious increases in BMD and Tb.Th, as well as prominent decreases in BS/BV and Tb.Sp in exo+Rh2 group. Essential role of gut-joint axis in RA Gut microbiota and metabolites have been deemed to be critical in developing RA. Strikingly, MSCs-exo and Rh2 can significantly ameliorate the disturbed gut microbiota in CIA model rats. The regulation of Candidatus_Saccharibacteria and Clostridium_XlVb may be the most pivotal. Concretely, Candidatus_Saccharibacteria modulates the metabolic pathway of vitamin digestion and absorption by pantothenic acid and vitamin D3 alterations. As for Clostridium_XlVb, it regulates 16(R)-HETE alterations in the arachidonic acid metabolic pathway. Conclusion MSCs-exo and Rh2 act synergistically to ameliorate RA by modulating the gut microbiota and metabolites, especially the reshaping of Candidatus_Saccharibacteria and Clostridium_XlVb abundance. Reference Zhou Z, Li Y, Wu S, et al. Host-microbiota interactions in collagen-induced arthritis rats treated with human umbilical cord mesenchymal stem cell exosome and ginsenoside Rh2. Biomed Pharmacother. Published online April 2, 2024. doi:10.1016/j.biopha.2024.116515 BONTAC Ginsenosides BONTAC has been dedicated to the R&D, manufacture and sale of raw materials for coenzyme and natural products since 2012, with self-owned factories, over 170 global patents as well as strong R&D team. BONTAC has rich R&D experience and advanced technology in the biosynthesis of rare ginsenosides Rh2/Rg3, with pure raw materials, higher conversion rate and higher content (up to 99%). Disclaimer This article is based on the reference in the academic journal. The relevant information is provided for sharing and learning purposes only, and does not represent any medical advice purposes. If there is any infringement, please contact the author for deletion. The views expressed in this article do not represent the position of BONTAC. Under no circumstances will BONTAC be responsible or liable in any way for any claims, damages, losses, expenses, or costs arising directly or indirectly from your reliance on the information and material on this website.